åŸææ®µéã®ãã€ãªå»è¬åäŒæ¥ã§ãã Aridis Pharmaceuticals, Inc. ã¯ãçåœãè
ããææçã®æ²»çã«å®å
šããã¢ãã¯ããŒãã«æäœ (mAb) ã䜿çšããæšçå
ç«çæ³ã®çºèŠãšéçºã«æ³šåããŠããŸããäž»å補ååè£ã¯ AR-301 ã§ãããã¯å
ç«ã°ãããªã³ 1 (IgG1) ã®å®å
šãã mAb ã§ãããS. aureus ã¢ã«ãã¡æ¯çŽ ã«ããèºææçã®æ²»çã察象ãšãã第 III çžããã¿ã«è©Šéšã宿œäžã§ããå瀟ã¯ãŸããã°ã©ã é°æ§èã® P. aeruginosa ãæšçãšãã第 II çžè©Šéšäžã®å®å
šãã IgG1 mAb AR-105ãP. aeruginosa è¡æž
å O11 ã«ããé¢å
èºç (HAP) ããã³äººå·¥åŒåžåšé¢é£èºç (VAP) ã®æ²»çã察象ãšãã第 IIa çžèšåºè©Šéšäžã®ãã IgM mAb AR-101 ãéçºäžã§ããã¢ã·ãããã¯ã¿ãŒã»ããŠããã«ããææçã®æ²»çè¬ãšããŠåèšåºæ®µéã«ããAR-401ãRSãŠã€ã«ã¹ã«å¯Ÿããå®å
šããIgG1 mAbåèšåºããã°ã©ã ã§ããAR-201ãå¢èæ§ç·ç¶çæ£è
ã®æ
¢æ§èºææçãšHAPããã³VAPæ£è
ã®æ¥æ§èºçã管çããããã®ç¬¬I/IIaçžèšåºè©Šéšäžã®æææçæ³ã§ããAR-501ãããã«ã軜çããäžççã®å
¥é¢ããŠããªãCOVID-19æ£è
ã®æ²»çè¬ãšããŠç¬¬I/IIçžèšåºè©Šéšäžã®2ã€ã®å®å
šããå
ç«ã°ãããªã³1ïŒIgG1ïŒmAbã®ã«ã¯ãã«ã§ããAR-712ãšAR-701ãéçºäžã§ãããã¢ãªãã£ã¹ã»ãã¡ãŒãã·ã¥ãŒãã£ã«ã«ãºã¯2003幎ã«èšç«ãããã«ãªãã©ã«ãã¢å·ãã¹ã¬ãã¹ã«æ¬ç€Ÿã眮ããŠããã